binding affinity News and Research

RSS

Engineered, high-affinity ACE2 receptors neutralize SARS-CoV-2

In a study published in the preprint server bioRxiv, researchers from the Kyoto Prefectural University of Medicine and Osaka University Japan, discuss how they engineered ACE2 to enhance its affinity to RBD in human cells.

17 Sep 2020

SARS-CoV-2 infection severity linked to superior humoral immunity against the S-protein

In a recent bioRxiv* preprint paper, Jenna J. Guthmiller et al., focus on the acute infection of SARS-CoV-2 and observe that the humoral immunity is distinctive with the infection stage and viral antigens.

16 Sep 2020

COVID specific IgA monoclonal antibodies may provide effective immunity against coronavirus

A new study by researchers at MassBiologics of UMass Medical School published in Nature Communications suggests that COVID specific IgA monoclonal antibodies may provide effective immunity in the respiratory system against the novel coronavirus - a potentially critical feature of an effective vaccine.

25 Aug 2020

Loss of supporting cells in olfactory epithelium causes loss of smell in COVID-19

In the current pandemic of COVID-19, many patients have reported symptoms of loss of smell and taste. The cellular basis of this phenomenon has not been satisfactorily explained so far. However, a new study published in the Briefings in Bioinformatics in August 2020 shows how this symptom is related to viral pathogenesis.

23 Aug 2020

SARS-CoV-2 poses significant threat to many marine mammal species

A new study conducted by researchers at Dalhousie University in Halifax, Canada, has found that many species of marine mammal are highly vulnerable to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

17 Aug 2020

Coronacept - A trap-and-destroy molecule against SARS-CoV-2

A new study published on the preprint server bioRxiv* in August 2020 reports a novel engineered molecule based on human and other mammalian orthologues of ACE2 fused with the Fc part of the antibody. This molecule interacts more tightly with the viral receptor-binding domain (RBD) to constitute a powerful immunoadhesin that targets the virus for destruction.

17 Aug 2020

De novo protein decoys that block SARS-CoV-2

Now, a new study published on the preprint server bioRxiv in August 2020 shows that computational design technology can be efficiently harnessed towards this end, producing new molecules to inhibit viral entry and replication.

5 Aug 2020

Picomolar inhibitors to SARS-CoV-2 proteins

Now, a new study published on the preprint server bioRxiv in August 2020 reports the development of mini-inhibitors based on computational design, that are suitable for such topical use.

4 Aug 2020

SARS-CoV-2 lured away and trapped by a new decoy version of ACE2

Researchers in the United States and Canada have engineered affinity-optimized “receptor traps” that prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from binding to and infecting cells.

3 Aug 2020

A new measles-based COVID-19 vaccine

Now, a new study by researchers from Germany's Paul Ehrlich Institute and published on the preprint server bioRxiv in July 2020 describes a potential vaccine based on the measles vaccine, which elicits both an antibody response and cellular immunity against the virus. This also protects against the measles virus. This could be a significant weapon in the fight against these two threats.

14 Jul 2020

Scientists discover common molecular feature found in SARS-CoV-2 neutralizing antibodies

A team led by scientists at Scripps Research has discovered a common molecular feature found in many of the human antibodies that neutralize SARS-CoV-2, the coronavirus that causes COVID-19.

13 Jul 2020

No unique viral sequences found in pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2

In contrast to previous hypotheses, researchers from the University College London and Great Ormond Street Hospital for Children NHS Foundation Trust found no evidence of unique viral sequences from patients with pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS). Their study is published on the medRxiv* preprint server.

12 Jul 2020

Tracing adaptation to ACE2 use in sarbecoviruses

A detailed study published on the preprint server bioRxiv in July 2020 argues that recombination accounts for the appearance of the ability of both SARS-CoV and SARS-CoV-2 to use the human angiotensin-converting enzyme (hACE) 2 as the binding receptor mediating viral infection of human cells.

8 Jul 2020

Study sheds new light on protein movement

Many of the most promising medicines under development are proteins, often antibodies, to help patients fight disease. These proteins must be purified as part of the manufacturing process -; a task that can be tricky and result in costly waste.

8 Jul 2020

SARS-CoV-2 spike protein hidden as pH changes

Now, a new study published on the preprint server bioRxiv in July 2020 reports the role of pH in helping the virus escape neutralization by antibodies, by inducing a key conformational switch.

7 Jul 2020

Highly effective and safe nanocrystal can fight against dangerous doses of radiation

Despite the wide application of radiation in diagnostics and treatments, there is still no magic material to protect people from radiation exposure.

6 Jul 2020

Spike protein and human ACE2 binding ability shows SARS-CoV-2 viral adaptation

A new study published on the preprint server bioRxiv in June 2020 reports some important findings that could shed light on this question. As the pandemic marches on, having claimed over 500,000 lives and caused well over 10 million infections to date, the task of defining and predicting factors that predispose to infectivity across species becomes ever more critical.

30 Jun 2020

SARS-CoV-2 has been evolving for at least 7 years

The burning question is how novel viruses acquire the ability to recognize, bind to and enter human cells for the first time – whether this is dependent only on viral proteins recognizing host cell proteins, or adaptations in other viral processes that allow replication in a human host.

25 Jun 2020

Mutational targets of SARS-CoV-2 receptor-binding domain for vaccine-antiviral development

The COVID-19 pandemic has spread throughout the whole world within six months, causing millions of infections and hundreds of thousands of deaths. Yet there is no effective vaccine or antiviral to deal with it.

18 Jun 2020

Impact Biomedical's COVID-19 research published in peer-reviewed scientific journal

SGX-listed Singapore eDevelopment Limited's wholly owned subsidiary Impact Biomedical Inc. announced today that their COVID-19 research with Global Research and Discovery Group Sciences, conducted in collaboration with Harvard Medical School and Vilotos Pharmaceutical, Inc., was published in the peer-reviewed scientific journal Molecules on June 11, 2020.